News Center
Most delays in a US IVF cycle trace back to the couple moving on two separate clocks: one partner's infectious disease panel expires before the other finishes screening, a retrieval day arrives with no frozen backup semen sample, or a required consent form sits unsigned because one signature needs a notary. Each of these can push a cycle back by several weeks or cancel it outright, and all three can be prevented before stimulation begins.
A US fertility clinic can only move as fast as its slowest required document. Every cycle runs on a chain of dependencies: lab work has to be current, legal consent has to be complete, and the male partner's contribution has to be available on the day the embryology laboratory needs it. The female partner's stimulation schedule anchors the calendar because her cycle determines the retrieval date. Everything the male partner does tends to feel flexible by comparison, so it slips.
This asymmetry shows up constantly in cross-city and cross-border couples. One partner lives near the clinic, attends the new-patient visit, completes blood work in the same week, and signs forms at the front desk. The other partner works overseas, travels for a job, or simply assumes the paperwork can wait. Weeks later, the cycle coordinator discovers a missing antibody titer, an unsigned page, or a semen sample that was never banked. The clinic then has to rebuild the schedule around a new blood draw, a notary appointment, or a frozen sample that does not exist.
The pattern is predictable enough that many coordinators now screen for it at the first visit. They ask where each partner lives, whether either travels during the expected treatment window, and whether both can appear in person before stimulation starts. Couples who answer honestly and act on the answers rarely lose time. Couples who treat the male partner's tasks as administrative afterthoughts lose weeks, sometimes an entire season, because some tests and some legal documents cannot be rushed once the calendar is already set.
Three failure points account for most of these losses. Each deserves a close look, because each has a specific fix that costs little and saves a lot.
Before any clinic will proceed, both partners need a communicable disease panel. In the United States, the regulatory frame comes from the FDA's rules for human cells and tissues under 21 CFR Part 1271, which set the screening logic for reproductive tissue, and clinics layer their own requirements on top following professional guidance from the American Society for Reproductive Medicine (ASRM). A typical panel covers HIV 1 and 2, hepatitis B surface antigen and core antibody, hepatitis C antibody, syphilis serology, and often HTLV, plus nucleic acid tests for gonorrhea and chlamydia. The female partner usually adds rubella and varicella immunity, blood type and antibody screen, and a set of metabolic and hormonal baselines.
The problem is that these results carry expiration windows, and the windows differ by test and by clinic. Many US laboratories treat HIV screening as current for roughly six to twelve months before retrieval, while certain other results are expected to fall within a shorter window relative to the egg retrieval date. Some clinics ask for specific items to be drawn within thirty days of the cycle. The exact rules vary from one laboratory director to the next, so the only reliable source is the written list your own clinic provides.
Here is how the mismatch plays out in practice. A wife completes her full panel in March during a work trip to the clinic's city. Her husband, based abroad, gets his blood drawn in June at a local hospital. The couple plans retrieval for December after several months of scheduling around work. In November, the coordinator runs a compliance check and finds that the wife's HIV result falls outside the clinic's twelve-month validity window for the December retrieval date, while one of the husband's hepatitis results is also stale. Both partners need redraws. The new results take five to ten days to process, the cycle start slips past the intended menstruation date, and the couple waits for the following month's cycle. One expired line item cost them six weeks.
A second, quieter version of the same failure involves where the blood was drawn. Many US clinics accept outside lab results only from facilities holding CLIA certification, the federal standard for US clinical laboratories. A report from a respected hospital in another country may be clinically excellent and still rejected on regulatory grounds, forcing a complete redraw at a US facility. Couples who discover this at the pre-cycle check lose the least; couples who discover it the week of stimulation lose the most.
A redraw itself is quick. The cost is the calendar around it: new results, a new review by the medical director, and a new alignment with the menstrual cycle. Planning the two partners' blood work as a single synchronized event removes one of the largest hidden sources of delay in the entire process.
Egg retrieval is scheduled around follicle development, and the window does not move for anyone's flight schedule. The laboratory expects a semen sample collected within a short period before use, typically after two to five days of abstinence, produced on site or delivered under conditions the lab specifies. If the male partner is on a plane, in a country with no way to courier a sample in time, or simply unable to produce under pressure that morning, the clinic faces three options, and two of them are expensive.
The first option is a previously cryopreserved backup sample. Semen freezes well, survives years in storage, and works for both standard insemination and ICSI. A sample banked during the initial workup, weeks before stimulation even begins, converts a potential cancellation into a non-event. The freezing itself is a routine service at essentially every US fertility center, and the storage and thaw fees are modest relative to the cost of a cancelled cycle, though exact pricing varies by clinic and should be confirmed directly.
The second option is surgical retrieval on the day of the egg retrieval, through a needle aspiration procedure such as TESA or PESA performed under local anesthesia. It works, but it adds operating room time, anesthesia charges, and a procedure the male partner must physically attend, which defeats the original problem if he cannot be present at all.
The third option is cancelling the cycle. Retrieved eggs without a usable sample cannot be fertilized, and embryos already planned for that month's transfer schedule fall apart. This is the outcome coordinators work hardest to prevent, and it happens most often to couples who assumed the male partner would simply be there.
Two practical details deserve attention. First, bank the sample at the clinic that will run the cycle whenever possible, because transporting frozen samples between facilities adds courier logistics and another set of chain-of-custody paperwork. Second, and this is the detail couples most often miss, a frozen sample is only useful if the consent to use it is already on file. A vial in the tank that the male partner has not authorized for fertilization is legally inert. The authorization should be signed at the same visit as the freezing, not left for later.
One more scenario deserves mention. Some couples discover mid-stimulation that the male partner's travel plans changed and he will miss retrieval day entirely, with no sample banked. At that point the choices narrow to surgical retrieval by a urologist, if one can be scheduled in time, or cancellation. Both are avoidable with a conversation during the workup, months earlier, about where each partner will physically be on the projected retrieval date.
Before embryos are created, frozen, transferred, or disposed of, both partners must sign legal consent documents covering fertilization, use in treatment, storage, and disposition in a range of contingencies, including what happens to embryos if the couple divorces or one partner dies. These forms are not clinic bureaucracy. They are the legal basis on which the laboratory touches the embryos at all, and fertility centers operate under external oversight, including FDA registration for reproductive tissue handling and accreditation inspections from bodies such as the College of American Pathologists, that make incomplete consent documentation a compliance problem for the clinic itself. A laboratory director who cannot produce a fully executed consent for embryos in storage is facing an audit finding, so the refusal to proceed without one is firm.
For couples in the same city, this is a ten-minute task at the front desk. For couples split across borders, it becomes one of the most underestimated delays in US fertility treatment. One partner signs in the clinic. The other signs a scanned copy emailed from another country. The clinic's legal review rejects the scan, because a signature on an international document generally needs either notarization by an authorized notary in the place of signing or an equivalent verification the clinic's counsel accepts. The cycle waits while someone in another jurisdiction hunts down a notary.
The verification layer depends on where the document is signed. Documents executed abroad for use in the United States commonly need an apostille under the Hague Apostille Convention, to which the US has been a party since 1981, and the apostille is issued by a designated authority in the country where the notarization happened. Processing times for apostilles range from days to weeks depending on the country and the office involved. An alternative for US citizens abroad is a notarial act performed at a US embassy or consulate, which the State Department provides by appointment. Some US states also permit remote online notarization, where a commissioned notary verifies identity over live video, and a number of clinics now accept these electronic notarizations, though acceptance varies by clinic and by state law.
The deeper point is that consent timing belongs to the laboratory, not to the couple's sense of readiness. A couple can be stimulated, monitored, and emotionally prepared, and the embryology team will still hold everything until the file shows both signatures, properly verified, on every required form. Legal paperwork completed in the same visit as the initial consultation, while both partners are in the same room, is the cheapest insurance available in this process.
Everything above reduces to a single discipline: treat the two partners as one project with shared deadlines, and front-load the tasks that cannot be compressed later. A workable approach looks like this.
None of this requires medical knowledge. It requires treating the male partner's file with the same urgency as the female partner's cycle, which is exactly how the clinic's compliance system already treats it.
Clinics differ meaningfully in how smoothly they handle split couples, and the differences show up in the workflows described above: whether they accept foreign lab reports, whether they support remote notarization, and whether they can bank and authorize a backup sample in a single visit. Couples in this situation tend to do well with centers that regularly serve patients who fly in, because those centers have already built the remote processes.
New Hope Fertility Center in Manhattan has long worked with international patients and runs remote coordination as a core part of its model, including upfront laboratory work completed closer to home and condensed on-site visits. For couples where one partner is based abroad, a center structured around minimal in-person visits reduces the number of trips on which both signatures and both blood draws must align.
HRC Fertility, with multiple locations across California, serves a large patient population traveling from the Asia-Pacific region, and its network of sites gives split couples more options for where each partner can complete blood work and paperwork within the same organization. A multi-site structure matters here: when one partner can be seen at a second location rather than only at the main laboratory, the synchronization window widens.
Spring Fertility, based in San Francisco and Oakland, operates its own laboratories and has built a reputation among Bay Area patients for transparent communication around protocols and scheduling. Couples with one partner traveling frequently for work on the West Coast may find the dual-city coverage useful for staggering appointments without duplicating paperwork.
These examples illustrate the selection logic rather than a ranking. Success rates and pricing vary by clinic and by patient profile, and the figures each center publishes should be read directly from its official reporting, including the clinic-specific outcomes reported through the Society for Assisted Reproductive Technology (SART). What a split couple should actually screen for is narrower: ask each candidate clinic three questions. Will you accept blood work from a named foreign or CLIA-certified laboratory? Do you accept remote online notarization or consular notarization for consent documents? Can you bank and authorize a backup semen sample in one visit? The answers separate centers that have solved the split-couple problem from centers that will improvise it at your expense.
Delays do not only happen before the first cycle. Couples returning for a frozen embryo transfer months later, or for a second child years later, frequently discover that their screening has aged out, that a consent needs re-execution after a change in marital status or state of residence, or that a stored sample's authorization does not cover the new treatment plan. A short re-verification pass roughly thirty days before any new cycle start catches these quietly: confirm every blood result's date against the projected retrieval or transfer date, confirm the consent file reflects the current plan, and confirm the backup sample, if one exists, still has a valid use authorization on file. Ten minutes of checking against the clinic's written requirements prevents the same three failures from recurring on round two.
The medical timeline of IVF, from protocol selection through transfer, is its own subject and is covered in detail elsewhere on this site. The three nodes above sit upstream of that timeline entirely, in the workup window where neither partner is taking medication yet. They are also the nodes where a couple's own coordination, more than any clinical factor, decides whether the cycle starts on the date everyone planned.
Sources and further verification: FDA regulations for human cells, tissues, and cellular or tissue-based products, 21 CFR Part 1271 (screening requirements for reproductive tissue); American Society for Reproductive Medicine (ASRM) guidance on infectious disease screening before assisted reproduction; Society for Assisted Reproductive Technology (SART) clinic-specific outcome reporting; US Department of State notarial and apostille information under the Hague Apostille Convention. Validity windows for specific tests, acceptance of foreign laboratory reports, and notarization requirements vary by clinic; confirm all requirements in writing with the fertility center you choose.
